Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A13 | Q16696 | 7/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MOK | Q9UQ07 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20468168 | 0.83 | LRRK2 (0.47) | CYP2A13LRRK2CYP2C9ALOX15HSD17B10 | |
| SCHEMBL633396 | 0.82 | CYP2A13 (0.54) | CYP2A13CYP2C9ALOX15HSD17B10HTT | |
| SCHEMBL18340154 | 0.75 | CYP2A13 (0.43) | CYP2A13LRRK2HSD17B10CNR2HTT | |
| SCHEMBL29846861 | 0.74 | CYP2A13 (0.49) | CYP2A13LRRK2CYP2C9ALOX15HSD17B10 | |
| SCHEMBL431122 | 0.74 | CYP2A13 (0.49) | CYP2A13LRRK2CYP2C9ALOX15HSD17B10 | |
| SCHEMBL23753781 | 0.74 | CYP2A13 (0.49) | CYP2A13LRRK2CYP2C9ALOX15HSD17B10 | |
| SCHEMBL20247420 | 0.74 | HTT (0.55) | CYP2A13LRRK2HTTMAPK1 | |
| SCHEMBL20247309 | 0.72 | TRPV4 (0.34) | — | |
| SCHEMBL1930020 | 0.72 | CYP2A13 (0.61) | CYP2A13CYP2C9ALOX15HSD17B10CYP3A4 | |
| SCHEMBL1117900 | 0.72 | CYP2A13 (0.61) | CYP2A13CYP2C9ALOX15HSD17B10CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3333157-B1 | VINYL COMPOUNDS AS FGFR AND VEGFR INHIBITORS | HARBIN ZHENBAO PHARMACEUTICAL CO LTD (CN) | 2020-12-23 | — | — | EP | disclosed |
| US-10519133-B2 | Vinyl compounds as FGFR and VEGFR inhibitors | MEDSHINE DISCOVERY INC. (CN) | 2019-12-31 | — | — | US | disclosed |
| US-20180222886-A1 | VINYL COMPOUNDS AS FGFR AND VEGFR INHIBITORS | Harbin Zhenbao Pharmaceutical Co., Ltd. (CN) | 2018-08-09 | — | — | US | disclosed |
| EP-3333157-A1 | VINYL COMPOUNDS AS FGFR AND VEGFR INHIBITORS | Harbin Zhenbao Pharmaceutical Co., Ltd. (CN) | 2018-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10519133-B2 | Vinyl compounds as FGFR and VEGFR inhibitors | FGFR1, FLT1, KDR | CYP2A13 1278/4885LRRK2 244/4885CYP2C9 319/4885 |
| US-20180222886-A1 | VINYL COMPOUNDS AS FGFR AND VEGFR INHIBITORS | FGFR1, FLT1, KDR | CYP2A13 1278/4885LRRK2 244/4885CYP2C9 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.